SCHEMBL14616807

SCHEMBL14616807

COCCn1c(-c2cnc(-c3ccc4scnc4c3)[nH]2)nc2c(N3CCOCC3)nccc21

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 1/20 0.40
▸ BRD4 O60885 1/20 0.37
▸ CYP1A2 P05177 7/20 0.34
▸ ALDH1A1 P00352 6/20 0.34
▸ HSD17B10 Q99714 6/20 0.34
▸ TSHR P16473 3/20 0.34
▸ CASP1 P29466 5/20 0.34
▸ CASP7 P55210 5/20 0.34
▸ USP2 O75604 4/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ HIF1A Q16665 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ FYN P06241 1/20 0.34
▸ GAK O14976 1/20 0.34
▸ GRIA1 P42261 1/20 0.34
▸ CACNG8 Q8WXS5 1/20 0.34
▸ TTK P33981 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14616812 0.93 RIPK2 (0.41) RIPK2
SCHEMBL14616813 0.93 RIPK2 (0.41) RIPK2ALDH1A1TSHRTTK
SCHEMBL14616825 0.92 RIPK2 (0.40) RIPK2CYP1A2ALDH1A1HSD17B10TSHR
SCHEMBL14616824 0.92 RIPK2 (0.40) RIPK2ALDH1A1TSHRTTK
SCHEMBL14616820 0.92 RIPK2 (0.39) RIPK2BRD4CYP1A2ALDH1A1HSD17B10
SCHEMBL14616811 0.91 TTK (0.38) RIPK2BRD4GAKTTK
SCHEMBL14616808 0.90 RIPK2 (0.37) RIPK2GAK
SCHEMBL14616809 0.90 RIPK2 (0.37) RIPK2GAK
SCHEMBL14616806 0.89 RIPK2 (0.39) RIPK2BRD4CYP1A2ALDH1A1HSD17B10
SCHEMBL14616816 0.88 RIPK2 (0.36) RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 RIPK2 255/4885BRD4 551/4885CYP1A2 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback